On Eve of RSA, Fortanix and Cybereason Talk Encryption, Cyberwar

the U.S. presidential election in 2016, and its infiltration of the controls at U.S. power plants and other utilities.

“This is the big thing,” Div says. “Not stealing credit cards.”

Div says he used to warn people a few years ago that soon, somebody would be able to manipulate the outcome of an election. They’d reply, “Give me what you have to smoke,” he says. “They still don’t believe it has happened.”

Although cyberactivity has evolved into “a legitimate tool of governments, military,” as well as the method of criminals, Div says, commercial security companies will eventually have the ability to overpower malicious activity by nation-states.

Meanwhile, Cybereason is extending its customer base from the United States outward to Japan, Europe, and other territories. Its customers span industries including finance, healthcare, insurance, and manufacturing. The defense contractor Lockheed Martin is a client, but Cybereason has no government customers at present, Div says.

Cybereason’s fundraising record is comparable to that of fellow Boston-area cybersecurity company Carbon Black, which filed papers with the SEC on Monday to prepare for a possible initial public offering. Does Cybereason plan to follow suit with an IPO?

“Definitely, yes,” Div says. “That is where we are aiming.” The company has more building to do, he says, but “it won’t be a long time to that discussion.”

Author: Bernadette Tansey

Bernadette Tansey is a former editor of Xconomy San Francisco. She has covered information technology, biotechnology, business, law, environment, and government as a Bay area journalist. She has written about edtech, mobile apps, social media startups, and life sciences companies for Xconomy, and tracked the adoption of Web tools by small businesses for CNBC. She was a biotechnology reporter for the business section of the San Francisco Chronicle, where she also wrote about software developers and early commercial companies in nanotechnology and synthetic biology.